IBDEI12T ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39077,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,39078,0)
 ;;=C92.A0^^148^1947^12
 ;;^UTILITY(U,$J,358.3,39078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39078,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39078,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,39078,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,39079,0)
 ;;=C92.51^^148^1947^13
 ;;^UTILITY(U,$J,358.3,39079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39079,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39079,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,39079,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,39080,0)
 ;;=C92.50^^148^1947^14
 ;;^UTILITY(U,$J,358.3,39080,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39080,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39080,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,39080,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,39081,0)
 ;;=C94.40^^148^1947^17
 ;;^UTILITY(U,$J,358.3,39081,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39081,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,39081,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,39081,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,39082,0)
 ;;=C94.42^^148^1947^15
 ;;^UTILITY(U,$J,358.3,39082,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39082,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,39082,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,39082,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,39083,0)
 ;;=C94.41^^148^1947^16
 ;;^UTILITY(U,$J,358.3,39083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39083,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,39083,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,39083,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,39084,0)
 ;;=D62.^^148^1947^18
 ;;^UTILITY(U,$J,358.3,39084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39084,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,39084,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,39084,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,39085,0)
 ;;=C92.41^^148^1947^19
 ;;^UTILITY(U,$J,358.3,39085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39085,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39085,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,39085,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,39086,0)
 ;;=C92.40^^148^1947^20
 ;;^UTILITY(U,$J,358.3,39086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39086,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39086,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,39086,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,39087,0)
 ;;=D56.0^^148^1947^21
 ;;^UTILITY(U,$J,358.3,39087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39087,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,39087,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,39087,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,39088,0)
 ;;=D63.1^^148^1947^23
 ;;^UTILITY(U,$J,358.3,39088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39088,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,39088,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,39088,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,39089,0)
 ;;=D63.0^^148^1947^24
 ;;^UTILITY(U,$J,358.3,39089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39089,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,39089,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,39089,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,39090,0)
 ;;=D63.8^^148^1947^22
 ;;^UTILITY(U,$J,358.3,39090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39090,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,39090,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,39090,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,39091,0)
 ;;=C22.3^^148^1947^26
 ;;^UTILITY(U,$J,358.3,39091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39091,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,39091,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,39091,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,39092,0)
 ;;=D61.9^^148^1947^27
 ;;^UTILITY(U,$J,358.3,39092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39092,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,39092,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,39092,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,39093,0)
 ;;=D56.1^^148^1947^29
 ;;^UTILITY(U,$J,358.3,39093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39093,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,39093,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,39093,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,39094,0)
 ;;=C83.79^^148^1947^31
 ;;^UTILITY(U,$J,358.3,39094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39094,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39094,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,39094,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,39095,0)
 ;;=C83.70^^148^1947^32
 ;;^UTILITY(U,$J,358.3,39095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39095,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,39095,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,39095,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,39096,0)
 ;;=D09.0^^148^1947^39
 ;;^UTILITY(U,$J,358.3,39096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39096,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,39096,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,39096,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,39097,0)
 ;;=D06.9^^148^1947^40
 ;;^UTILITY(U,$J,358.3,39097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39097,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,39097,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,39097,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,39098,0)
 ;;=D06.0^^148^1947^42
 ;;^UTILITY(U,$J,358.3,39098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39098,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,39098,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,39098,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,39099,0)
 ;;=D06.1^^148^1947^43
 ;;^UTILITY(U,$J,358.3,39099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39099,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,39099,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,39099,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,39100,0)
 ;;=D06.7^^148^1947^41
 ;;^UTILITY(U,$J,358.3,39100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39100,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,39100,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,39100,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,39101,0)
 ;;=D04.9^^148^1947^44
 ;;^UTILITY(U,$J,358.3,39101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39101,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,39101,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,39101,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,39102,0)
 ;;=C91.11^^148^1947^47
 ;;^UTILITY(U,$J,358.3,39102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39102,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,39102,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,39102,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,39103,0)
 ;;=C91.10^^148^1947^48
 ;;^UTILITY(U,$J,358.3,39103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39103,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,39103,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,39103,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,39104,0)
 ;;=C92.11^^148^1947^49
 ;;^UTILITY(U,$J,358.3,39104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39104,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,39104,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,39104,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,39105,0)
 ;;=C92.10^^148^1947^50
 ;;^UTILITY(U,$J,358.3,39105,1,0)
 ;;=^358.31IA^4^2
